FDA Puts Cumberland’s Ifetroban on Fast Track for Cardiomyopathy in DMD The US FDA granted Fast Track designation to ifetroban, an oral thromboxane receptor antagonist, for cardiomyopathy in patients with DMD.

Cumberland Pharmaceuticals announced that the @fda.gov has granted #FastTrack Designation to #Ifetroban (#Dyscorban®), the company’s novel oral therapy for #Cardiomyopathy in patients with #DuchenneMuscularDystrophy (DMD).

Read more: https://bit.ly/4rTzo4j

#RareDisease #DMD #MedSky